Lantern Pharma (LTRN) Current Assets (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Current Assets came in at $7.1 million in Q1 2026, down 66.11% YoY from $20.8 million in Q1 2025, and down 34.67% on a QoQ basis from $10.8 million in Q4 2025.
Lantern Pharma (LTRN) Current Assets (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Current Assets data on file, last reported at $7.1 million in Q1 2026.
- Quarterly Current Assets fell 66.11% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (down 66.11% YoY) and the FY2025 annual result came in at $10.8 million, down 57.21% from the prior year.
- Current Assets slipped to $7.1 million in Q1 2026, from $10.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $67.7 million in Q1 2022 to a low of $7.1 million in Q1 2026.
- A 5-year average of $38.3 million and a median of $39.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets slipped 17.97% — and 2026, when it sank 66.11%.
- Tracing LTRN's Current Assets over 5 years: stood at $58.7 million in 2022, then slipped by 26.19% to $43.3 million in 2023, then sank by 41.75% to $25.2 million in 2024, then tumbled by 57.21% to $10.8 million in 2025, then slumped by 34.67% to $7.1 million in 2026.
- The last three Current Assets figures came in at $7.1 million (Q1 2026), $10.8 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 7.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.06 Mn |
| Dec 31, 2025 | 10.80 Mn |
| Sep 30, 2025 | 13.46 Mn |
| Jun 30, 2025 | 17.20 Mn |
| Mar 31, 2025 | 20.82 Mn |
| Dec 31, 2024 | 25.25 Mn |
| Sep 30, 2024 | 29.92 Mn |
| Jun 30, 2024 | 35.29 Mn |
| Mar 31, 2024 | 39.47 Mn |
| Dec 31, 2023 | 43.34 Mn |
| Sep 30, 2023 | 47.43 Mn |
| Jun 30, 2023 | 51.04 Mn |
| Mar 31, 2023 | 55.17 Mn |
| Dec 31, 2022 | 58.72 Mn |
| Sep 30, 2022 | 62.02 Mn |
| Jun 30, 2022 | 65.66 Mn |
| Mar 31, 2022 | 67.66 Mn |
| Dec 31, 2021 | 72.72 Mn |
| Sep 30, 2021 | 76.34 Mn |
| Jun 30, 2021 | 82.13 Mn |